Current Opinion in Neurology was launched in 1988. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of neurology is divided into 14 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Journal's Section Editors for this issue. SECTION EDITORS Massimo FilippiMassimo FilippiMassimo Filippi is currently Full Professor of Neurology at Vita-Salute San Raffaele University, Milan, Italy; Director of the Residency School in Neurology, and President of the Bacherlor's Degree in Physiotherapy at the same University. He is also Chair of the Neurology and Neurorehabilitation Units, Director of the MS Center, Director of the Neurophysiology Service, and Director of the Neuroimaging Research Unit at the IRCCS Scientific Institute San Raffaele, Milan. His research activity has always focused on the definition of the mechanisms leading to progressive accumulation of irreversible physical disability and cognitive impairment in various neurological conditions. He is member of various national and international Scientific Societies and Boards where he covered or is covering institutional roles. He is author of over 1200 papers, Editor-in-Chief of the Journal of Neurology, Associate Editor of Human Brain Mapping, and member of the Editorial Boards of many international scientific journals. He is very often requested as speaker and/or chairman in national and international neurological congresses. In 2001, Prof. Filippi was awarded the Rita Levi Montalcini Prize for his outstanding contributions to the study of MS. Per SvenningssonPer SvenningssonPer Svenningsson is Professor in Neurology at the Karolinska Institutet, Sweden. He received his MD and PhD from Karolinska Institutet in 1998. He then did his postdoctoral training in the laboratory of the Nobel laureate Paul Greengard at the Rockefeller University, USA, between 1999 and 2003. His studies concerned GPCR neuropharmacology and signal transduction and included the discovery of p11 as an important modulator of serotonin neurotransmission. He performed his residency in Neurology at Karolinska University Hospital and became Professor in 2012 and senior consultant in 2016. Since 2018, he is also part time Professor of Neurodegeneration at King's College London, UK. His research interests include GPCR pharmacology, Parkinson's disease both its motor and non-motor aspects and atypical parkinsonism. Studies are conducted both in preclinical models and in specimens from patients. The goal is to identify novel targets for improved diagnostics and pharmacological receptor-based treatments. Biochemical, histological, pharmacological, molecular biological and behavioral techniques are used. In the clinics, he is conducting clinical trials with therapies aiming to slow down progression of Parkinson's disease or to treat debilitating symptoms of the disease. He has published more than 300 articles. Since 2014, he is member of the Nobel Assembly annually awarding the Nobel Prize in Physiology or Medicine. He delivered the Eurolife Distinguished Medal Lecture in Barcelona in 2017 and was awarded the Arvid Carlsson Prize in 2020.